Navigation Links
Targeted investigational therapy potential to overcome crizotinib resistance in lung cancers
Date:10/20/2013

BOSTON PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

About 3 to 5 percent of lung cancers harbor ALK gene abnormalities. The drug crizotinib (Xalkori), which blocks ALK protein kinase activity, was approved in August 2011 by the U.S. Food and Drug Administration for the treatment of patients who have these lung cancers. Although robust responses to crizotinib are observed for lung cancers harboring ALK gene abnormalities, the majority eventually become resistant to the effects of the drug. In many cases, resistance arises because of genetic mutations in ALK.

"Resistance to targeted therapies such as crizotinib is a major challenge when treating patients with cancer," said Tod Smeal, Ph.D., associate research fellow in the Oncology Research Unit at Pfizer Inc. in San Diego, Calif. "Our goal is to take advantage of everything we have learned about designing drugs that target kinases like ALK and the ways in which lung cancers become resistant to crizotinib to develop the best next-generation ALK inhibitor we can.

"Our preclinical studies suggest that we are making progress toward achieving our goal: PF-06463922 has potent ALK-inhibiting activity, it is capable of inhibiting all the crizotinib-resistant ALK mutants so far detected in patients, and it can efficiently access the brain. We are excited about these preclinical results and very hopeful that they will translate into meaningful responses in the clinic."

After carefully designing PF-06463922, Smeal and colleagues first showed in cell assays that it potently inhibited the activity of ALK and all eight of the mutant forms of ALK known to cause resistance to crizotinib
'/>"/>

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Targeted therapeutics for colon cancer to be presented at AACR meeting
2. First targeted nanomedicine to enter human clinical studies
3. Highly targeted irradiation as good as whole breast radiotherapy in early stage cancer
4. Dana-Farber: Study reports first success of targeted therapy in type of non-small cell lung cancer
5. Inflammatory pathway spurs cancer stem cells to resist HER2-targeted breast cancer treatment
6. Killer infections targeted by hospital study
7. Lower risk of serious side-effects in trials of new targeted drugs
8. Treating drug resistant cancer through targeted inhibition of sphingosine kinase
9. Pitt: Targeted oxidation-blocker prevents secondary damage after traumatic brain injury
10. Deadly witch hunts targeted by grassroots womens groups
11. Large lung cancer study shows potential for more targeted therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 Effective today, the wellness ... Highmark Blue Cross Blue Shield Insurance. Owned by ... Nourish Nutrition and Health opened for business earlier ... Wexford. , The basis of the services ... informing clients on the simplicity of leading a ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 A ... business and technology startups is now available from ... marketing agency based in the Chicago region. The ... software and information technology (IT), services, ecommerce, healthcare, ... , Marketing disciplines critical to startup success include ...
(Date:7/30/2014)... Printing whole new organs for transplants sounds like something ... technology could one day make actual kidneys, livers, hearts ... In the ACS journal Langmuir , scientists are ... that takes them a step closer to realizing their ... , Yong Huang and colleagues note that this idea ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The 3D ... seen and touched in our new 50,000 square foot ... (just behind Target). , Projectorscreenstore.com is one of the ... range of sophisticated technology and Audio/Visual products for education, ... with Makerbot, the leading manufacturer of 3D printers for ...
(Date:7/30/2014)... July 30, 2014 The Hearing Aid ... five years to 2014. Following a multiyear drop during ... demographic trends, the expansion of private healthcare coverage and, ... that Hearing Aid Clinics industry revenue will ... billion during the five years to 2014. , According ...
Breaking Medicine News(10 mins):Health News:Nourish Nutrition and Health Now Accepting Highmark Insurance 2Health News:Startup Marketing Practice Launched by Modern Marketing Partners 2Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 3
... in the topoisomerase II alpha ( TOP2A ) gene ... compared with non-anthracycline-based regimens, according to a study in ... of the National Cancer Institute. The increased responsiveness ... tumors carry an amplification of the HER 2 ...
... Health & Science University Knight Cancer Institute will evaluate ... Seattle, Wash.) is as effective in delivering highly precise ... it has been in those with prostate cancer. , ... for prostate cancer, and it is our hope to ...
... Senior Living, Inc. (NYSE: SRZ ) today ... its Bank Credit Facility, which eliminates all financial covenants, ... 2009 maturity date."We are very pleased that our bank ... through its maturity date," said Mark Ordan, Sunrise,s chief ...
... NSAIDs can cause liver or stomach illness in ... (HealthDay News) -- Many over-the-counter painkillers and fever ... the potential danger of liver damage and stomach ... will have to include these warnings on all ...
... of the American Academy of Disaster Medicine,s (AADM), Gary ... from a disaster medicine perspective on the recent swine ... why improvements are needed to the U.S. public health ... or pathogen; how disaster medicine specialists are helping other ...
... Smithfield Foods, Inc. (NYSE: SFD ) ... no clinical signs or symptoms of the presence of ... its employees at its joint ventures in Mexico. As ... officials and are submitting samples from their swine herds ...
Cached Medicine News:Health News:Gene alterations associated with response to anthracycline therapy for breast cancer 2Health News:OHSU Knight Cancer Institute to study new radiation technology for head, neck cancer 2Health News:Sunrise Signs Twelfth Amendment to Bank Credit Facility through December 2, 2009 2Health News:Sunrise Signs Twelfth Amendment to Bank Credit Facility through December 2, 2009 3Health News:Sunrise Signs Twelfth Amendment to Bank Credit Facility through December 2, 2009 4Health News:FDA Adds New Label Warnings to Over-the-Counter Painkillers 2Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 2Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 3Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 4Health News:Smithfield Foods Says North American Influenza Not Present in Any of Its Worldwide Operations and Pork is Safe to Eat 2
(Date:7/30/2014)... Silicon Valley Bank, the bank of the ... that examines the merger, acquisition and IPO activity of ... the annual report based on 2013 data, venture investment ... started tracking the data in 2005. "2013 ... healthcare M&A activity over the last few years, the ...
(Date:7/30/2014)... NEW YORK , July 30, 2014 ... of new products for oncology supportive care, announced that ... has been featured in an article on OncLive.com titled, ... Head and Neck Cancers."  Dr. Steve Sonis , ... the growing demand seen in the oncology community for ...
(Date:7/30/2014)...   Medical Equipment Solutions, Corp. are pleased ... of Defense (US Army) contract valued at over $2 ... diagnostic machine and technical support staffing. As an 8-A ... Business Administration (SBA), Medical Equipment is proud to support ... medical diagnostic equipment. The SBA 8-A certification is a ...
Breaking Medicine Technology:Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Medical Equipment Solutions Corp. Awarded $2 Million contract To Service DoD 2
... GREENWOOD VILLAGE, Colo. , July 21 Ampio Pharmaceuticals, Inc. ... clinical trial of Optina™ for the treatment of diabetic macular edema, an ... vision loss in patients with diabetes mellitus. , ... Ampio Pharmaceuticals has completed a formal agreement with ...
... Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp. ... contract from the U.S. Army to develop an investigational device ... deployed to the Army under a separate contract. Under the ... of the Signal-X6 system that will incorporate automated heart sound ...
Cached Medicine Technology:Ampio Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Optina™ 2Zargis Awarded U.S. Army Contract 2Zargis Awarded U.S. Army Contract 3
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Steroid eluting pacemaker leads...
Medicine Products: